fms-Like Tyrosine Kinase 3
"fms-Like Tyrosine Kinase 3" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A receptor tyrosine kinase that is involved in HEMATOPOIESIS. It is closely related to FMS PROTO-ONCOGENE PROTEIN and is commonly mutated in acute MYELOID LEUKEMIA.
Descriptor ID |
D051941
|
MeSH Number(s) |
D08.811.913.696.620.682.725.400.020 D12.776.543.750.630.020 D12.776.624.664.700.114
|
Concept/Terms |
fms-Like Tyrosine Kinase 3- fms-Like Tyrosine Kinase 3
- fms Like Tyrosine Kinase 3
- Fetal Liver Kinase-2
- Fetal Liver Kinase 2
- Fetal Liver Kinase-3
- Fetal Liver Kinase 3
- CD135 Antigens
- Antigens, CD135
- CD135 Antigen
- Antigen, CD135
- Stem Cell Tyrosine Kinase 1
|
Below are MeSH descriptors whose meaning is more general than "fms-Like Tyrosine Kinase 3".
Below are MeSH descriptors whose meaning is more specific than "fms-Like Tyrosine Kinase 3".
This graph shows the total number of publications written about "fms-Like Tyrosine Kinase 3" by people in this website by year, and whether "fms-Like Tyrosine Kinase 3" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1996 | 0 | 1 | 1 |
2003 | 0 | 1 | 1 |
2004 | 0 | 7 | 7 |
2005 | 0 | 2 | 2 |
2006 | 4 | 1 | 5 |
2007 | 2 | 1 | 3 |
2008 | 2 | 8 | 10 |
2009 | 4 | 0 | 4 |
2010 | 3 | 5 | 8 |
2011 | 10 | 4 | 14 |
2012 | 7 | 5 | 12 |
2013 | 12 | 4 | 16 |
2014 | 7 | 3 | 10 |
2015 | 5 | 3 | 8 |
2016 | 6 | 5 | 11 |
2017 | 7 | 4 | 11 |
2018 | 6 | 7 | 13 |
2019 | 13 | 5 | 18 |
2020 | 6 | 6 | 12 |
2021 | 6 | 5 | 11 |
2022 | 3 | 12 | 15 |
2023 | 1 | 7 | 8 |
2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "fms-Like Tyrosine Kinase 3" by people in Profiles.
-
Feasible diet and circadian interventions reduce in?vivo progression of FLT3-ITD-positive acute myeloid leukemia. Cancer Med. 2024 Jan; 13(2):e6949.
-
TP-0184 inhibits FLT3/ACVR1 to overcome FLT3 inhibitor resistance and hinder AML growth synergistically with venetoclax. Leukemia. 2024 01; 38(1):82-95.
-
Cigarette smoke exposure accelerates AML progression in FLT3-ITD models. Blood Adv. 2023 11 14; 7(21):6624-6629.
-
Inhibition of menin, BCL-2, and FLT3 combined with a hypomethylating agent cures NPM1/FLT3-ITD/-TKD mutant acute myeloid leukemia in a patient-derived xenograft model. Haematologica. 2023 09 01; 108(9):2513-2519.
-
Optimising maintenance therapy after transplantation: sorafenib's role in patients with FLT3-ITD acute myeloid leukaemia. Lancet Haematol. 2023 08; 10(8):e559-e561.
-
Concomitant targeting of FLT3 and BTK overcomes FLT3 inhibitor resistance in acute myeloid leukemia through the inhibition of autophagy. Haematologica. 2023 06 01; 108(6):1500-1514.
-
Ferroptosis vulnerability in FLT3-mutant leukemia. Trends Cancer. 2023 07; 9(7):524-525.
-
FLT3 inhibitors upregulate CXCR4 and E-selectin ligands via ERK suppression in AML cells and CXCR4/E-selectin inhibition enhances anti-leukemia efficacy of FLT3-targeted therapy in AML. Leukemia. 2023 06; 37(6):1379-1383.
-
Causal linkage of presence of mutant NPM1 to efficacy of novel therapeutic agents against AML cells with mutant NPM1. Leukemia. 2023 06; 37(6):1336-1348.
-
Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes. Am J Hematol. 2022 Dec; 97(12):1599-1606.